Tatsuki R Kataoka
Overview
Explore the profile of Tatsuki R Kataoka including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
100
Citations
1011
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Maeshima Y, Kataoka T, Vandenbon A, Hirata M, Takeuchi Y, Suzuki Y, et al.
EBioMedicine
. 2024 Aug;
107:105271.
PMID: 39173531
Background: Breast cancer cells suppress the host immune system to efficiently invade the lymph nodes; however, the underlying mechanism remains incompletely understood. Here, we aimed to comprehensively characterise the effects...
2.
Takano T, Masuda N, Ito M, Inoue K, Tanabe Y, Kawaguchi K, et al.
Breast Cancer Res Treat
. 2024 May;
207(1):33-48.
PMID: 38767786
Purpose: The randomized phase 2 Neo-peaks study examined usefulness of neoadjuvant trastuzumab emtansine + pertuzumab (T-DM1 + P) following docetaxel + carboplatin + trastuzumab + pertuzumab (TCbHP) as compared with...
3.
Matsubara S, Iguchi R, Ogasawara M, Nakamura H, Kataoka T, Shiraishi A, et al.
Int J Mol Sci
. 2024 Feb;
25(4).
PMID: 38396656
A wide variety of bioactive peptides have been identified in the central nervous system and several peripheral tissues in the ascidian type A (). However, hemocyte endocrine peptides have yet...
4.
Jahangir C, Page D, Broeckx G, Gonzalez C, Burke C, Murphy C, et al.
J Pathol
. 2024 Jan;
262(3):271-288.
PMID: 38230434
Recent advances in the field of immuno-oncology have brought transformative changes in the management of cancer patients. The immune profile of tumours has been found to have key value in...
5.
Yamaguchi A, Kawaguchi K, Kawanishi K, Maeshima Y, Nakakura A, Kataoka T, et al.
Breast Cancer Res Treat
. 2023 Dec;
204(2):261-275.
PMID: 38123790
Purpose: The efficacy of carboplatin is non-equivalent to that of cisplatin (CDDP) for various tumor types in curative settings. However, the role of CDDP in operable triple-negative breast cancer (TNBC)...
6.
Nakagawa R, Minamiguchi S, Kataoka T, Fujikura J, Masui T, Fujimoto M, et al.
Diagn Pathol
. 2023 Oct;
18(1):115.
PMID: 37864201
Background: Adult non-neoplastic hyperinsulinemic hypoglycemia (ANHH), also known as adult-onset nesidioblastosis, is a rare cause of endogenous hyperinsulinemic hypoglycemia in adults. This disease is characterized by diffuse hyperplasia of pancreatic...
7.
Thagaard J, Broeckx G, Page D, Jahangir C, Verbandt S, Kos Z, et al.
J Pathol
. 2023 Aug;
260(5):498-513.
PMID: 37608772
The clinical significance of the tumor-immune interaction in breast cancer is now established, and tumor-infiltrating lymphocytes (TILs) have emerged as predictive and prognostic biomarkers for patients with triple-negative (estrogen receptor,...
8.
Page D, Broeckx G, Jahangir C, Verbandt S, Gupta R, Thagaard J, et al.
J Pathol
. 2023 Aug;
260(5):514-532.
PMID: 37608771
Modern histologic imaging platforms coupled with machine learning methods have provided new opportunities to map the spatial distribution of immune cells in the tumor microenvironment. However, there exists no standardized...
9.
Nishimura T, Kakiuchi N, Yoshida K, Sakurai T, Kataoka T, Kondoh E, et al.
Nature
. 2023 Jul;
620(7974):607-614.
PMID: 37495687
Recent studies have documented frequent evolution of clones carrying common cancer mutations in apparently normal tissues, which are implicated in cancer development. However, our knowledge is still missing with regard...
10.
Nakamura H, Matsuzaki T, Ito K, Nakagawa R, Asano L, Nishikido H, et al.
Pathol Int
. 2023 Jun;
73(9):406-412.
PMID: 37341622
Cutaneous xanthoma consist of foam cells that originate from monocytes or macrophages and accumulate in perivascular areas of the skin. The main component of these cells is oxidized low-density lipoprotein...